Frontiers in Endocrinology (Sep 2021)

Whole Exome Sequencing Uncovered the Genetic Architecture of Growth Hormone Deficiency Patients

  • Chenxi Yu,
  • Chenxi Yu,
  • Chenxi Yu,
  • Bobo Xie,
  • Bobo Xie,
  • Bobo Xie,
  • Zhengye Zhao,
  • Zhengye Zhao,
  • Sen Zhao,
  • Sen Zhao,
  • Lian Liu,
  • Lian Liu,
  • Xi Cheng,
  • Xi Cheng,
  • Xiaoxin Li,
  • Xiaoxin Li,
  • Bingyan Cao,
  • Jiashen Shao,
  • Jiashen Shao,
  • Jiajia Chen,
  • Hengqiang Zhao,
  • Hengqiang Zhao,
  • Zihui Yan,
  • Zihui Yan,
  • Chang Su,
  • Yuchen Niu,
  • Yuchen Niu,
  • Yanning Song,
  • Liya Wei,
  • Yi Wang,
  • Xiaoya Ren,
  • Lijun Fan,
  • Beibei Zhang,
  • Chuan Li,
  • Chuan Li,
  • Chuan Li,
  • Baoheng Gui,
  • Baoheng Gui,
  • Baoheng Gui,
  • Yuanqiang Zhang,
  • Lianlei Wang,
  • Shaoke Chen,
  • Shaoke Chen,
  • Shaoke Chen,
  • Jianguo Zhang,
  • Jianguo Zhang,
  • Jianguo Zhang,
  • Zhihong Wu,
  • Zhihong Wu,
  • Zhihong Wu,
  • Zhihong Wu,
  • Chunxiu Gong,
  • Xin Fan,
  • Xin Fan,
  • Xin Fan,
  • Nan Wu,
  • Nan Wu,
  • Nan Wu,
  • Nan Wu

DOI
https://doi.org/10.3389/fendo.2021.711991
Journal volume & issue
Vol. 12

Abstract

Read online

PurposeCongenital growth hormone deficiency (GHD) is a rare and etiologically heterogeneous disease. We aim to screen disease-causing mutations of GHD in a relatively sizable cohort and discover underlying mechanisms via a candidate gene-based mutational burden analysis.MethodsWe retrospectively analyzed 109 short stature patients associated with hormone deficiency. All patients were classified into two groups: Group I (n=45) with definitive GHD and Group II (n=64) with possible GHD. We analyzed correlation consistency between clinical criteria and molecular findings by whole exome sequencing (WES) in two groups. The patients without a molecular diagnosis (n=90) were compared with 942 in-house controls for the mutational burden of rare mutations in 259 genes biologically related with the GH axis.ResultsIn 19 patients with molecular diagnosis, we found 5 possible GHD patients received known molecular diagnosis associated with GHD (NF1 [c.2329T>A, c.7131C>G], GHRHR [c.731G>A], STAT5B [c.1102delC], HRAS [c.187_207dup]). By mutational burden analysis of predicted deleterious variants in 90 patients without molecular diagnosis, we found that POLR3A (p = 0.005), SUFU (p = 0.006), LHX3 (p = 0.021) and CREB3L4 (p = 0.040) represented top genes enriched in GHD patients.ConclusionOur study revealed the discrepancies between the laboratory testing and molecular diagnosis of GHD. These differences should be considered when for an accurate diagnosis of GHD. We also identified four candidate genes that might be associated with GHD.

Keywords